Greenwich LifeSciences Presents Early FLAMINGO-01 Data at ASCO 2026 — Greenwich LifeSciences, Inc.

Event summary

Greenwich LifeSciences' abstract on GLSI-100's immune response data accepted for ASCO 2026 poster presentation.
Non-HLA-A*02 open-label arm of FLAMINGO-01 Phase III trial fully enrolled with 250 patients.
Preliminary data shows 70-80% reduction in recurrence rate after Primary Immunization Series (PIS).
Delayed-type-hypersensitivity (DTH) reactions increased by ~290% post-GLSI-100 treatment.

The big picture

Greenwich LifeSciences' ASCO presentation marks a critical milestone in validating its immunotherapy approach for preventing breast cancer recurrences. The company's Phase III FLAMINGO-01 trial represents one of the most comprehensive efforts to date targeting HER2-positive patients, with potential implications for expanding treatment options beyond current standards. The early data suggesting comparable efficacy across different HLA types could significantly broaden GLSI-100's addressable patient population if confirmed.

What we're watching

Clinical Efficacy Validation: Whether the preliminary 70-80% recurrence rate reduction in non-HLA-A*02 patients will be sustained through full FLAMINGO-01 trial completion.
Regulatory Pathway: The pace at which Greenwich LifeSciences can translate these Phase III results into potential FDA approval for GLSI-100.
Market Differentiation: How the 70-80% efficacy compares to existing breast cancer recurrence prevention therapies offering 20-50% reduction.